Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women

Journal of Obstetrics and Gynaecology Research

Volumn 41, Issue 2, 2015, Pages 254-263

  De Medeiros, Sebastião Freitas ^a,b,c   Barbosa, Jacklyne Silva ^c   Yamamoto, Márcia Marly Winck ^b,c  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^c Tropical Institute of Reproductive Medicine and Menopause   (Brazil)

Author keywords

adrenal stimulation; enzyme activity; hyperandrogenism; polycystic ovary syndrome; steroidogenesis

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROSTENEDIONE; CORTODOXONE; DEOXYCORTICOSTERONE; ESTRADIOL; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; PRASTERONE; PROLACTIN; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; THYROTROPIN; 3 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE II; 3BETA HYDROXY DELTA5 STEROID DEHYDROGENASE; ANDROGEN;

ADULT; BODY HEIGHT; BODY MASS; BODY SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FAT MASS; FEMALE; FREE THYROXINE INDEX; HIP CIRCUMFERENCE; HUMAN; HYPERANDROGENIC POLYCYSTIC OVARY SYNDROME; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; NORMOANDROGENIC POLYCYSTIC OVARY SYNDROME; OVARY POLYCYSTIC DISEASE; REVIEW; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYMOLOGY; HYPERANDROGENISM; METABOLISM; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; ANDROGENS; ANDROSTENEDIONE; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE; ESTRADIOL; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN; POLYCYSTIC OVARY SYNDROME; PROGESTERONE REDUCTASE; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; YOUNG ADULT;

EID: 84921692509     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12524     Document Type: Review

References (52)

1. Gilling-Smith C, Story H, Rogers V, Franks S,. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 1997; 47: 93-99.
2. Moran C, Reyna R, Boots LS, Azziz R,. Adrenocortical hyperresponsiveness to corticotrophin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril 2004; 81: 126-131.
3. Gambineri A, Forlani G, Munarini A, et al. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 210-218.
4. Payne AH, Hales DB,. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004; 25: 947-970.
5. de Medeiros SF, Gil-Junior AB, Barbosa JS, Isaias ED, Yamamoto MM,. New insights into steroidogenesis in normo- and hyperandrogenic polycystic ovary syndrome patients. Arq Bras Endocrinol Metab 2013; 57: 437-444.
6. Zawadski JK, Dunaif A,. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In:, Dunaif AGJ, Haseltine F, (eds). Polycystic Ovary Syndrome. Boston: Blackwall Scientific, 1992; 377-384.
7. Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245.
8. Gil-Junior AB, Rezende AP, do Carmo AV, Duarte EI, de Medeiros MM, de Medeiros SF,. Adrenal androgen participation in the polycystic ovary syndrome. Rev Bras Gynecol Obstet 2010; 32: 541-548.
9. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO,. The prevalence and features of the polycystic ovary syndrome in a unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
10. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
11. Rosenfield RL, Barnes RB, Cara JF, Lucky AW,. Dysregulation of cytochrome P450c17 alpha as a cause of polycystic ovary syndrome. Fertil Steril 1990; 53: 785-791.
12. Sahin Y, Kelestimur F,. The frequency of late-onset 21-hydroxylase and 11β-hydroxilase deficiency in women with polycystic ovary syndrome. Eur J Endocrinol 1997; 137: 670-674.
13. Ditkoff EC, Fruzzetti F, Chang L, Stanczyck FZ, Lobo RA,. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 603-607.
14. Bayoumy HA, Alothman AN,. Adrenal contribution to polycystic ovary syndrome. Med Princ Pract 2001; 10: 151-155.
15. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z,. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162.
16. Nestler JE, Jakubowicz DJ,. Lean women with polycycstic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075-4079.
17. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97: 3709-3716.
18. New MI, Lorenzen F, Lerner AJ,. Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab 1983; 57: 320-326.
19. WHO Consultion on Obesity. Obesity: Preventing and Managing the Global Epidemic. Report of A World Health Organization Consultation. World Health Organization Technical Report Series 894. Geneva: World Health Organization, 2000.
20. James WPT, Department of Health and Social Security and Medical Research Council Group. Research on Obesity. A Repot of the DHSS/MRC Group. London: Her Majesty's Stationary office, 1976.
21. Valdez R,. A simple model-based index of abdominal adiposity. J Clin Epidemiol 1991; 44: 955-956.
22. Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristic of polycystic ovary syndrome (PCOS): Comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88: 4682-4688.
23. Wild RA, Vesely S, Beebe L, Whitsett T, Owen W,. Ferriman Gallwey self-scoring I: Performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4112-4114.
24. Sowers SM, Derby C, Jannausch ML, Torrens JI, Pasternak R,. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003; 88: 4904-4910.
25. Dolfing JG, Tucker KE, Lem CM, Uittenbogaart J, Verzijl JC, Schweitzer DH,. Low 11-deoxycortisol to cortisol conversion reflects extra-adrenal factors in the majority of women with normo-gonadotrophic normo-estrogenic infertility. Hum Reprod 2003; 18: 333-337.
26. Costa-Barbosa FA, Carvalho VM, Nakamura OH, Bachega TA, Vieira JG, Kater CE,. Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 21-hydroxylase deficiency: Further characterization of classic and non-classic patients and heterozygote carriers. J Endocrinol Invest 2011; 34: 587-592.
27. Ryan KJ, Petro Z,. Steroid biosynthesis by human ovarian granulosa and thecal cells. J Clin Endocrinol Metab 1966; 26: 46-52.
28. Nelson VL, Legro RS, Stratus JF III, McAllister JM,. Aumented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endo 1999; 13: 946-957.
29. Kushnir MM, Rockwood AL, Roberts WL, et al. Development and performance evaluation of a tandem mass spectrometry assay for 4 adrenal steroids. Clin Chem 2006; 52: 1559-1567.
30. Legro RS, Schlaff WD, Diamond MP, et al. Total testosterone assays in women with polycystic ovary syndrome: Precision and correlation with hirsutism. J Clin Endocrinol Metab 2010; 95: 5305-5313.
31. Barnes RB, Rosenfield RL, Burnstein S, Ehrmann DA,. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320: 559-565.
32. Çolak R, Keleştimur F, Unlühizarci K, Bayram F, Sahin Y, Tutuş A,. A comparison between the effects of low dose (1 μg) and standard dose (250 μg) ACTH stimulation tests on adrenal P450c17α enzyme activity in women with polycystic ovary syndrome. Eur J Endocrinol 2002; 147: 473-477.
33. Escobar-Morreale HF, Sanchõn R, San Millán JL,. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93: 527-533.
34. Rosencrantz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 1106-1113.
35. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA,. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids 2006; 71: 751-759.
36. Nestler JE, Whitfield JB, Williams TY, et al. Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects. J Clin Endocrinol Metab 2002; 87: 682-686.
37. Lin D, Black SM, Nagahama Y, Miller WL,. Steroid 17 α-hydroxylase and 17,20-lyase activities of P450c 17: Contributions of serine 106 and P450 reductase. Endocrinology 1993; 132: 2498-2506.
38. Auchus RJ, Lee TC, Miller WL,. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273: 3158-3165.
39. Wake DJ, Stand M, Rask E, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol 2007; 66: 440-446.
40. L'Allemand D, Eiholzer U, Rousson V, et al. Increased adrenal androgen levels in patients with Prader-Willi syndrome are associated with insulin, IGF-I, and leptin, but not with measures of obesity. Horm Res 2002; 58: 215-222.
41. Biason-Lauber A, Zachmann M, Schoenle EJ,. Effect of leptin on CYP17 enzymatic activies in human adrenal cells: New insights in the onset of adrenarche. Endocrinology 2000; 141: 1446-1454.
42. Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA,. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: Expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82: 2343-2349.
43. Pang S, Lerner A, Stoner E, et al. Late-onset adrenal steroid 3β-hydroxysteroid dehydrogenase deficiency a cause of hirsutism in pubertal ans postpubertal womem. J Clin Endocrinol Metab 1985; 60: 428-438.
44. Cobin RH, Futterweit W, Fiedler RP, Thornton JC,. Adrenocorticotrophic hormone testing in idiopathic hirsutism and polycystic ovarian disease: A test of limited usefulness. Fertil Steril 1985; 44: 224-226.
45. Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3β-hydroxylase deficiency. J Clin Endocrinol Metab 2002; 87: 2611-2622.
46. Cassorla AK, Pfeiffer DG, Albertson BD, Loriaux DL,. The effects of estradiol and progesterone on rat ovarian 17-hydroxylase and 3β-hydroxysteroid dehydrogenase activities. Steroids 1983; 41: 95-98.
47. Elda-Geva T, Hurwitz A, Vecsei P, Palti Z, Roesler A,. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. N Engl J Med 1990; 323: 855-863.
48. Perry JE, Stalvey JR,. Gonadal steroids modulate adrenal fasciculata 3β-hydroxysteroid dehydrogenase-isomerase activity in mice. Biol Reprod 1992; 46: 73-82.
49. Tonetta SA, De Vinna RS, diZerega GS,. Thecal cell 3-beta hydroxysteroid dehydrogenase activity: Modulation by human chorionic gonadotropin, progesterone, estradiol-17 beta and dihydrotestosterone. J Steroid Biochem 1987; 28: 77-82.
50. Kershaw EE, Flier JS,. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 6: 2548-2556.
51. Pall M, Azziz R, Beires J, Pignatelli D,. The phenotype of hirsute women: A comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril 2010; 94: 684-689.
52. Azziz R, Bradley JEL, Potter D, Boots LR,. Adrenal androgen excess in women: Lack of a role for 17-hydroxylase and 17, 20-lyase dysregulation. J Clin Endocrinol Metab 1995; 80: 400-405.